# A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.

> **NCT04899271** · PHASE2 · TERMINATED · sponsor: **Dompé Farmaceutici S.p.A** · enrollment: 25 (actual)

## Conditions studied

- New-onset Type 1 Diabetes

## Interventions

- **DRUG:** Ladarixin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04899271
- **Lead sponsor:** Dompé Farmaceutici S.p.A
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-14
- **Primary completion:** 2023-04-27
- **Final completion:** 2023-10-11
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** low recruitment rate
- **Last updated:** 2025-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04899271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04899271, "A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04899271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*